Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 20/20 | 0.69 |
| ▸ | CHRM2 | P08172 | 12/20 | 0.69 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.69 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL411291 | 0.94 | CCR5 (0.69) | CCR5CHRM2CHRM1CHRM3KCNH2 | |
| SCHEMBL12796167 | 0.88 | CCR5 (0.83) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL14679205 | 0.84 | CCR5 (0.57) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL410793 | 0.84 | CCR5 (0.83) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL12420339 | 0.84 | CCR5 (0.73) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL18541410 | 0.84 | CCR5 (0.73) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL12531415 | 0.83 | CCR5 (0.74) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL13484306 | 0.82 | CCR5 (0.84) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL16503427 | 0.81 | CCR5 (0.84) | CCR5CHRM2CHRM1CHRM3 | |
| SCHEMBL13334539 | 0.80 | CCR5 (0.76) | CCR5CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059154-A1 | CCR5 ANTAGONISTS AS PROPHYLACTICS FOR PREVENTING HIV INFECTION AND METHODS OF INHIBITING TRANSMISSION OF SAME | MERCK SHARP & DOHME CORP. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059154-A1 | CCR5 ANTAGONISTS AS PROPHYLACTICS FOR PREVENTING HIV INFECTION AND METHODS OF INHIBITING TRANSMISSION OF SAME | CCR5, CCL5, CCR2 | CCR5 1/4885CHRM2 322/4885CHRM1 305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.